Funding for this research was provided by:
Supported by Novartis Pharmaceuticals Inc. Canada and sponsored by the Ontario Clinical Oncology Group. Grant number not applicable.
Received: 8 October 2019
Accepted: 31 January 2020
First Online: 21 February 2020
: M.V. reports honoraria from Novo Nordisk, Merck, AbbVie, Bausch Health and Sanofi, and he is a consultant/advisor for Novo Nordisk, AbbVie, Bausch Health. G.P. reports that his spouse is employed and owns stock at Roche Canada. He is a consultant/advisor for Takeda DSMB. J.R.G. reports consultant/advisory activities for Roche/Genentech, Merck, Pfizer, Novartis, Puma, AstraZeneca, Sandoz/Hexal, Immunomedics, Genomic Health, Radius, InBiomotion. K.I.P. reports consultant/advisory activities for Pfizer, Roche, Amgen, Novartis, Eisai, Genomic Health Inc., Myriad Genetic Laboratories. All remaining authors have declared no conflicts of interest.